HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cyanidin prevents the hyperproliferative potential of fibroblast-like synoviocytes and disease progression via targeting IL-17A cytokine signalling in rheumatoid arthritis.

Abstract
The hyperplastic phenotype of fibroblast-like synoviocytes (FLSs) plays an important role for synovitis, chronic inflammation and joint destruction in rheumatoid arthritis (RA). Interleukin 17A (IL-17A), a signature pro-inflammatory cytokine effectively influences the hyperplastic transformation of FLS cells and synovial pannus growth. IL-17A cytokine signalling participates in RA pathology by regulating an array of pro-inflammatory mediators and osteoclastogenesis. Cyanidin, a key flavonoid inhibits IL-17A/IL-17 receptor A (IL-17RA) interaction and alleviates progression and disease severity of psoriasis and asthma. However, the therapeutic efficacy of cyanidin on IL-17A cytokine signalling in RA remains unknown. In the present study, cyanidin inhibited IL-17A induced migratory and proliferative capacity of FLS cells derived from adjuvant-induced arthritis (AA) rats. Cyanidin treatment reduced IL-17A mediated reprogramming of AA-FLS cells to overexpress IL-17RA. In addition, significantly decreased expression of IL-17A dependent cyr61, IL-23, GM-CSF, and TLR3 were observed in AA-FLS cells in response to cyanidin. At the molecular level, cyanidin modulated IL-17/IL-17RA dependent JAK/STAT-3 signalling in AA-FLS cells. Importantly, cyanidin activated PIAS3 protein to suppress STAT-3 specific transcriptional activation in AA-FLS cells. Cyanidin treatment to AA rats attenuated clinical symptoms, synovial pannus growth, immune cell infiltration, and bone erosion. Cyanidin reduced serum level of IL-23 and GM-CSF and expression of Cyr 61 and TLR3 in the synovial tissue of AA rats. Notably, the level of p-STAT-3 protein was significantly decreased in the synovial tissue of AA rats treated with cyanidin. This study provides the first evidence that cyanidin can be used as IL-17/17RA signalling targeting therapeutic drug for the treatment of RA and this need to be investigated in RA patients.
AuthorsSnigdha Samarpita, Ramamoorthi Ganesan, Mahaboobkhan Rasool
JournalToxicology and applied pharmacology (Toxicol Appl Pharmacol) Vol. 391 Pg. 114917 (03 15 2020) ISSN: 1096-0333 [Electronic] United States
PMID32044269 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Elsevier Inc. All rights reserved.
Chemical References
  • Anthocyanins
  • Il17a protein, rat
  • Interleukin-17
  • STAT3 Transcription Factor
  • Stat3 protein, rat
  • cyanidin
  • Janus Kinases
Topics
  • Animals
  • Anthocyanins (therapeutic use)
  • Arthritis, Experimental (drug therapy)
  • Arthritis, Rheumatoid (drug therapy, pathology)
  • Cell Movement (drug effects)
  • Disease Progression
  • Fibroblasts (drug effects, pathology)
  • Gene Expression Regulation (drug effects)
  • Interleukin-17 (metabolism)
  • Janus Kinases (biosynthesis, genetics)
  • Male
  • Rats
  • Rats, Wistar
  • STAT3 Transcription Factor (biosynthesis, genetics)
  • Signal Transduction (drug effects)
  • Synovial Fluid (drug effects)
  • Synovial Membrane (pathology)
  • Synoviocytes (drug effects, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: